Alcohol use disorder (AUD) remains one of the most pervasive and challenging conditions in addiction medicine. While abstinence-based models have long dominated treatment, harm reduction strategies—especially pharmacological interventions—are increasingly recognized for their ability to reduce cravings, prevent relapse, and support long-term recovery. Two FDA-approved medications stand out in this space: Naltrexone and Antabuse (Disulfiram).